THE IMPACT OF PIOGLITAZONE THERAPY ON GLYCEMIC CONTROL, BLOOD PRESSURE AND INFLAMMATORY MARKERS IN PATIENTS WITH DIABETES MELLITUS

Basit Öğe Kaydı
dc.contributor.authorOrdu, Serkan
dc.contributor.authorGüngör, A.
dc.contributor.authorYüksel, H.
dc.contributor.authorAlemdar, R.
dc.contributor.authorÖzhan, H.
dc.contributor.authorYazıcı, M.
dc.contributor.authorAlbayrak, S.
dc.date.accessioned2020-04-30T23:33:47Z
dc.date.available2020-04-30T23:33:47Z
dc.date.issued2010
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000276112900007en_US
dc.description.abstractAim. The aim of our study was to investigate the effect of pioglitazone on glycemic and blood pressure control, on inflammation markers in diabetic patients. Patients and methods. Forty-nine diabetic patients who had been followed up as outpatients for 2.7 years and HbA1c was >7% were included in the study. The patients had never received thiazolidinedione therapy before. Clinical, metabolic variables, high-sensitive C-reactive protein (hsCRP), homocysteine (HCY) and asymmetric dimethylarginine (ADMA) levels were measured. 30 mg pioglitazone were administered. The patients were followed up for six months and all the measurements were re-evaluated for comparison. Results. Body mass index (BMI) significantly increased after treatment. Fasting glucose, HbA1c and HsCRP were decreased. Insulin resistance was improved and HOMA-IR index was decreased after pioglitazone treatment [8 (+/- 6.5) vs 4(+/- 3.1); p<0.00011. Pioglitazone improved lipid metabolism. Mean total cholesterol and LDL cholesterol levels were decreased and HDL cholesterol was increased after treatment. The decrease in triglyceride and homocysteine levels did not reach significance. Mean ADMA level did not change after therapy [0.62 (+/- 0.39) vs 0.61 (+/- 0.44); p=0.85]. Conclusion. Pioglitazone treatment in type 2 DM produced significant improvements in measures of glycemic control, plasma lipids, blood pressure and homocysteine levels. Pioglitazone had no influence on ADMA levels.en_US
dc.identifier.doi10.4183/aeb.2010.73en_US
dc.identifier.endpage82en_US
dc.identifier.issn1841-0987
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage73en_US
dc.identifier.urihttps://doi.org/10.4183/aeb.2010.73
dc.identifier.urihttps://hdl.handle.net/20.500.12684/5044
dc.identifier.volume6en_US
dc.identifier.wosWOS:000276112900007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherEditura Acad Romaneen_US
dc.relation.ispartofActa Endocrinologica-Bucharesten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAsymmetric dimethylarginine (ADMA)en_US
dc.subjectdiabetes mellitusen_US
dc.subjecthigh-sensitive C-reactive proteinen_US
dc.subjecthomocysteineen_US
dc.subjectinsulin resistanceen_US
dc.subjectpioglitazoneen_US
dc.titleTHE IMPACT OF PIOGLITAZONE THERAPY ON GLYCEMIC CONTROL, BLOOD PRESSURE AND INFLAMMATORY MARKERS IN PATIENTS WITH DIABETES MELLITUSen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
5044.pdf
Boyut:
118.77 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu